Takeaway
- Resveratrol may be an effective adjunct to angiotensin receptor blockers (ARBs) for reducing urinary albumin excretion in patients with diabetic nephropathy.
Why this matters
- Resveratrol is naturally occurring and derived from plants, and is widely reported for its anti-inflammatory, antioxidant, antiapoptotic and cytoprotective effects but no studies have evaluated its effects on albuminuria.
Study design
- Randomised controlled trial of 60 patients (resveratrol group, n=30; placebo, n=30) with type 2 diabetes and albuminuria between March 2016 and February 2017.
- Patients received either resveratrol (500 mg/day) or placebo for 90 days; losartan (12.5 mg/day) was administered to all patients.
- Funding: Shiraz University of Medical Sciences.
Key results
- Significant reduction in mean urine albumin/creatinine ratio was observed in resveratrol group (−46.4 mg/g; P<.001) vs placebo group (29.9 mg/g; P<.001) and remained significant after adjustments (P<.001).
- In the resveratrol group, increase in levels of nitric oxide (NO; P<.001), superoxide dismutase (P<.001), glutathione peroxidase (P<.001) and catalase (P<.001), and significant decrease in malondialdehyde (P=.03) was observed.
- Every 1 cm decrease in waist circumference and 1 μmol/L increase in NO was associated with 9.4 mg/g and 4.0 mg/g reduction in urine albumin/creatinine ratio, respectively.
Limitations
- Short duration of study.
- Inflammatory markers were not measured.
References
References